Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Randomized trial shows significant weight loss in adults with obesity, indicating mazdutide benefits metabolic regulation.

Weight loss was significantly higher in participants receiving mazdutide compared to placebo, with a mean change of -20.0% for Cohort 1 and -21.0% for Cohort 2.
At Week 20, around 66.7% of Cohort 1 and 75.0% of Cohort 2 achieved weight loss of at least 15%, while no placebo participants reached even 5% weight loss.
This was a randomized, double-blind, placebo-controlled trial involving 32 adults with overweight or obesity, receiving weekly injections for 20 weeks.
Mazdutide shows potential for improved metabolic regulation, with no serious adverse events reported, though mild gastrointestinal issues occurred.

Bhattachar et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark